Member Info for Nextlink

I take it you are referring to Drones.
This company has very little involvement with Drones.

Could be seeing the last of Venn Life Sciences 30 million shares.

Like you I held on Ofex.
As to reinstating the Dividend I feel we are very much in a
Growth stage.
We have cash to draw down for further acquisitions, which
will increase debt in the near term.
In that case I would happily continue to forgo a Dividend to see reducing debt
and increasing profit.

Since the Suspension Notice in September 2016 we have had
three announcements up to March this year.
In the last six weeks we have had nine.
It is hard to believe there is not a potential deal in the offing.
I have located a new private Company listed with Companies House, which
may indicate the target.
However, apart from being wrong, I will say no more on a public forum, to
avoid causing any issues to Highway Capital at this critical stage.

Regardless of a possible Trading Update, results are due in June.
Here we are with almost half the current Market Cap in cash.
Steps taken last year to permit payment of a Dividend.
A few investments reaching maturity.

Resolution 13 if passed will allow the Directors to put aside the requirement to offer
new shares, up to 52 million to existing shareholders.
This authority to be valid until the next AGM.
If they were to execute an RTO this would be a necessary step.

That's my take on this.
Hoping they have a target in sight.
All this frantic activity suggests that they do.

I agree insufficient cash was raised and current SP is aggravating this.
However Journalists are cheap and two a penny.
Good Software Developers are scarce and expensive.
Daily Mash integrated with their existing business should generate
economies of scale.
That said I think it will be a slow climb back to IPO SP with a strong
possibility of Dilution en route.
I've put these in the bottom draw and concentrating on other investments.

I was impressed by the progress they were making on all fronts
when they updated us on 24th January.
Over two months since that update, given they are not hanging about,
more news cannot be far off.

Looking at recent trades it is fair to say there is very little
confidence.
Their last Trading Update in November states that trading is in line with expectations.
That statement being made since they drew on £1.9 million unsecured loan note.
It certainly suggests that the results will be reasonable.
Personally I am not tempted by the weak SP rather see the results on Tuesday first.

Possible.
Then again we could just see a repeat of today if someone is stake building.

http://4965zs3ha2l125fk78zkozo3.wpengine.netdna-cdn.com/wp-content/uploads/ReNeuron-corporate-presentation-Mar-2019.pdf

Good to see they are moving ahead on the retinitis pigmentosa (RP).
I believe they were originally scheduled for June.

directinggas - shareholders would not have to worry about what
Scancell would be worth in administration as they would have lost
their entire investment.
I would hope administration never arises.

Knowlesi sadly I agree with you that the sp is far more likely to
continue it's downward trend.
Fortunately I exited several years ago and nothing I have seen of
late leads me to consider buying at this time.
Plenty of other opportunities out there, most of my shares are
going up, not something that can often be said of Scancell of late.

Another which has a candidate for inherited retinal dystrophy
https://www.biopharma-reporter.com/Article/2019/02/25/Roche-acquires-Spark-Therapeutics-for-4.3bn

Spark Theraputics have many other trials, in particular a treatment for haemophilia.
Reneuron is clearly not worth $4.3bn, perhaps not even £500 million

As I understand it MM's try to keep their book square.
So tend not to have many shares at the end of each days trading.
They may have a small free float to satisfy Normal Market size.

Only bought in this month on RP results.
Until recently I was only aware of their stroke trials, which have absorbed
huge amounts of cash.
Fascinated to see they have other trials, at much earlier stages.
Only starting to look at the Retinal Pigmentosa field.
I see that Biogen have bought Nightstar Therapeutics
Whilst at Phase 111, their treatment is for a rare inherited condition.
So Reneuron whilst at a very early stage has a much bigger market.
No doubt other companies out there, just begining to look.
Reckon we have a good week ahead -8.5% of Invesco's shares missing.
It can't all be Private Investors buying that amount.

Looks as if this could be Reneurons Summer.
Everything they have is valued at zero at this sp which is
covered by cash.
I understand there is considerable cash burn.
I am only here on the retinal stem cell results.
Particularly with the deals being made in that sphere.

Everything suggests the Market viewed Digitalbox's listing value
as to high at this point in time.
However it does look as if we are now seeing a recovery.

Very informative. I certainly feel more comfortable with my investment.